Replies to post #20771 on Biotech Values

[io_io]

Praveen / TEVA

<<<"also MNTA is planning to file a biogeneric for copaxone(copaxone's patents have already expired), Also most of TEVA's revenues are from copaxone if I am right.....Short TEVA?">>>

I don't usually (hardly ever in fact) short a stock; OTOH I didn't know about this generic-Copaxone issue ...... I would suppose the Ranbaxy news is not good for generic-makers in general ?

[DewDiligence]

>most of TEVA's revenues are from copaxone if I am right...<

No—not even close. TEVA has total annualized sales of more than $5B (1.32B in the latest quarter), and Copaxone represents 10-15% of the total, after adjusting for TEVA’s 50% stake. (SNY owns the other 50% of Copaxone.)

>…and also MNTA is planning to file a biogeneric for Copaxone…<

That’s news to me. Can you provide a source? T.i.a. Dew

[Biopharm investor]

Copaxone's patent status


"copaxone's patents have already expired"

That's not correct. Copaxone's earliest patent doesn't expire until May 24, 2014.

http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=020622&Product_No=001&....

This is not to say that someone cannot certify against the patent and challenge it, but it most certainly has NOT expired, and will not do so for quite some time.